PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsOzanimod
Zeposia(ozanimod)
Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-03-25. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis and ulcerative colitis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 2, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 3.
Download report
Favorite
FDA Novel Drug Approvals 2020
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Zeposia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ozanimod hydrochloride
Tradename
Company
Number
Date
Products
ZEPOSIABristol Myers SquibbN-209899 RX2020-03-25
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zeposiaNew Drug Application2024-08-30
zeposia zeposiaNew Drug Application2021-06-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
relapsing-remitting multiple sclerosisEFO_0003929D020529—
Agency Specific
FDA
EMA
Expiration
Code
OZANIMOD HYDROCHLORIDE, ZEPOSIA, BRISTOL
2025-03-25NCE
2024-05-27I-860
Patent Expiration
Patent
Expires
Flag
FDA Information
Ozanimod Hydrochloride, Zeposia, Bristol
116800502038-09-30DS, DPU-2774, U-3740
102398462030-11-15U-3132
84815732029-05-14DS, DPU-2774
87963182029-05-14DS, DP
93822172029-05-14U-2774
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA38: Ozanimod
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G3512631425
Ulcerative colitisD003093EFO_0000729K51—2521018
SclerosisD012598——1142815
Relapsing-remitting multiple sclerosisD020529EFO_0003929——143714
ColitisD003092EFO_0003872K52.9—142714
UlcerD014456MPATH_579——142714
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K50—25—17
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.1—1———1
Alzheimer diseaseD000544EFO_0000249F03—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———9———211
Liver diseasesD008107EFO_0001421K70-K771————1
Gastrointestinal diseasesD005767——1————1
Digestive system diseasesD004066EFO_0000405K92.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Medication adherenceD055118EFO_0006344—————11
FatigueD005221—R53.83————11
Neuromyelitis opticaD009471EFO_0004256G36.0————11
Nerve degenerationD009410——————11
Inflammatory bowel diseasesD015212EFO_0003767—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOzanimod
INNozanimod
Description
Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.
Classification
Small molecule
Drug classimmunomodulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N
Identifiers
PDB—
CAS-ID1306760-85-9
RxCUI—
ChEMBL IDCHEMBL3707247
ChEBI ID—
PubChem CID52938427
DrugBankDB12612
UNII IDZ80293URPV (ChemIDplus, GSRS)
Target
Agency Approved
S1PR1
S1PR1
Organism
Homo sapiens
Gene name
S1PR1
Gene synonyms
CHEDG1, EDG1
NCBI Gene ID
1901
Protein name
sphingosine 1-phosphate receptor 1
Protein synonyms
CD363, Endothelial differentiation G-protein coupled receptor 1, endothelial differentiation, sphingolipid G-protein-coupled receptor, 1, S1P receptor 1, S1P receptor Edg-1, Sphingosine 1-phosphate receptor Edg-1, sphingosine 1-phosphate receptor EDG1
Uniprot ID
Q9NYN8
Mouse ortholog
S1pr1 (13609)
sphingosine 1-phosphate receptor 1 (Q9R235)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zeposia – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,660 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,929 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use